

CRISPR PATENT LANDSCAPE

January 2017



IPStudies

Intangible assets deserve closer scrutiny

Copyright

- Unless otherwise specified, all content included on this document, such as text, graphics, logos, button icons, images, audio and video clips, digital downloads, data compilations, and software, **including but not limited to IPStudies surveys**, is the property of IPStudies SARL and protected by international copyright laws.
- **You agree not to copy, reproduce, duplicate, sell, resell, or exploit for any commercial purposes, any portion of this content.**
- **You may not re-use and/or extract part of this content outside of your legal entity, institutional or corporate environment without IPStudies's express consent in writing.**

Our team



Corinne LE BUHAN, PhD

ICT Expert

IP Strategy & Management

- Funded IPStudies in 2010 to help Swiss & EU high-tech SMEs develop and execute their IP valuation plans using the latest patent analytics tools and trends
- 15 years experience in IP strategy and management – former VP Knowledge Management of NagraVision-Kudelski Group, in charge with patents (200 families), standards, R&D collaborations, licensing and technical publications portfolios
- Teaches international licensing practices and IP strategy at IEEPI – EU Horizon2020 expert on Innovation in SMEs 2013-2015
- ICT Technology Expert for various licensing facilitators and aggregators in France, Germany and the US
- University postgraduate in management of innovation and intellectual property (University of Strasbourg, 2008), PhD in Communications Science (EPFL, 1998), MSc in Electrical Engineering (INSA Rennes, 1994)
- Experienced with Patbase, EPO/RegisterPlus, USPTO/PAIR
- International network of IP practitioners and licensing managers - Member LES, IEEE, AROPI, AAIEEPI



Fabien PALAZZOLI, PhD

Life Sciences Expert

Patent Analysis & Landscapes

- Joined IPStudies in 2013 to develop the IP analytics offering in life sciences & biotechnology
- 9+ years experience in technology transfers, patent mapping/landscaping and FTO-driven research intelligence for the French public sector and biotech SMEs - former IP analytics sales manager for FIST SA, the CNRS technology transfer office
- Author/co-author of 18 scientific and technical publications/communications, as well as one book chapter
- Life sciences patent analyst for various biotech/medtech SMEs in Switzerland and in Europe
- PhD in Life Sciences (*Exploitation of patent information in a public research laboratory: identification of technological niches in bioproduction and gene therapy*, University of Tours, 2011), MSc in Biotechnology and Law (University of Tours, 2007)
- Experienced with Orbit, Patbase, Intellixir, patent offices databases
- International network of patent information analysts




Table of contents

- Methodology
- Overall trends of the CRISPR patent database
 - Temporal distribution of patent filings (2002-2016)
 - Temporal distribution of patent filings by type of players (2002-2016)
 - World map of priority filings
 - Temporal distribution of priority filings (2002-2016)
 - World map of patent extensions
 - Main patent applicants/assignees
 - Temporal distribution of filings of applicants/assignees
 - Co-filings between applicants/assignees
- Breakdown of the CRISPR patent database
 - Breakdown by Claim coverage of patent families
 - Breakdown of the patent portfolio
 - Temporal distribution of filings
 - Positioning of applicants/assignees
 - Breakdown by Components
 - Breakdown of the patent portfolio
 - Temporal distribution of filings
 - Positioning of the applicants/assignees
 - Breakdown by Chimeric proteins
 - Breakdown of the patent portfolio
 - Temporal distribution of filings
 - Positioning of applicants/assignees
- Main forward cited patent families
- Appendices – licensing announcements, affiliation mapping of players present in the patent landscape




Temporal distribution of patent filings by type of players (2002-2016)



- 707 filings by institutional applicants/assignees (61.7%),
- 358 filings by industrial applicants/assignees (31.2%),
- 48 filings by individual inventors (4.2%),
- 33 co-filings between industrial applicants/assignees and institutional applicants/assignees (2.9%).
- The years 2015 and 2016 are not complete due to the delay of publication of 18 months in most jurisdictions.




Main patent applicants/assignees (≥ 7 patent families)



- Affiliates & subsidiaries have been gathered under their parent company (Danisco with DuPont...). Co-filings are counted for each co-owner: a patent application co-filed between the MIT, the Harvard University and the Broad Institute is counted once for each applicant.
- The patent portfolio of DuPont comprises historical patent families on CRISPR sequences dealing with the typing of bacterial strains, cultures with improved phage resistance and applications for preparing food.



Co-filings between applicants/assignees




- The co-filing map shows the co-filings between applicants/assignees. The same type of link can be found when an assignment occurred between two players, giving the historical applicants as well as the new owners.

License announcements – SAMPLE PAGE (4)

Licensor	Scope	Licensee	Date
Toolgen	Worldwide license & sublicenses rights for research applications including the development and sale of reagents, cell lines, and animal models, as well as rights for high throughput screening, diagnostics, and bioproduction. ToolGen retains its rights in broad areas including high throughput screening, diagnostics, bioproduction, plant biotechnology and gene/cell therapy.	Thermo Fisher Scientific	2015/03
DuPont	The cross-license enables Caribou to develop and utilize CRISPR-Cas technology for product development in multiple fields including human and animal therapeutics, diagnostics, industrial biotechnology, research tools, and certain agriculture segments. The DuPont license to Caribou includes rights to the Cas9-mediated genome editing intellectual property owned by Vilnius University and exclusively licensed to DuPont.	Caribou Biosciences	2015/10
Caribou Biosciences	Multi-faceted agreement includes the cross-licensing of key intellectual property, a research collaboration, and financial investments by DuPont in Caribou, a developer of CRISPR-Cas technologies.	DuPont	2015/10
Crispr Therapeutics	\$105 million upfront—\$75 million in cash, \$30 million equity investment - future development, regulatory and sales milestones of up to \$420 million for each of up to six CRISPR-Cas9-based treatments for which Vertex has agreed to license exclusive development rights. Royalties on future sales.	Vertex	2015/10
ERS Genomics	Non-exclusively licensed patents related to CRISPR-Cas9 genome-editing technology to Regeneron Pharmaceuticals for use in drug discovery and development	Regeneron	2015/11

Breakdown of the CRISPR patent database (1)

The 1146 patent families have been manually reviewed and classified




- A patent family can be classified in several categories (e.g. 'Genome Editing' and 'Therapeutic application' and 'Human cell-subject' and 'CRISPR-Cas system'...).



Breakdown of the CRISPR patent database (2)

The 1146 patent families have been manually reviewed and classified




- A patent family can be classified in several categories (e.g. 'Genome Editing' and 'Therapeutic application' and 'Human cell-subject' and 'CRISPR-Cas system'...).




Breakdown by Claim coverage of patent families

Breakdown of the patent portfolio




Breakdown by Components

Breakdown of the patent portfolio



Breakdown by Chimeric proteins

Breakdown of the patent portfolio



Further analytics for your specific needs with the online database

- Zoom on patent portfolios of specific applicants
- Zoom on patents filed in a country/region (US, EP, CN...), within a time period
- Zoom on patents covering an application, a dedicated technology, a specification or a functional subset
- Link to online patent office registers to review latest legal status

Search

Geography

Originating countries

Protected countries

Extended countries

Dates

Organizations

Authors

Custom Fields

Patents

IPC

ECLA

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307</

Order

This is only a sample report with partial data. Our full offer includes:

- an **analysis of the patent landscape**, covering 1146 patent families, worldwide
- a **synthesis of IP strategy findings**, to visualize key trends in terms of patent applicants, collaboration networks, competitor technology positioning, key inventors and R&D white spaces out of the landscape
- an **on-line access to the 1146 patent families set**, so you can visualize, navigate, focus and extract the most relevant patent data according to your specific needs.



IPStudies

Contact us today for an offer at

sales@ipstudies.ch

+41 79 787 57 46

